Advertisement

Virtual CME Satellite Symposium

Seperate registration required. Click button below to register.

Register Now
From Sledgehammer to Selective: Transforming Cytotoxic Potency Through Targeted Treatments for Advanced or Metastatic Urothelial Cancer

Join us for a virtual CME satellite symposium at

Earn up to 1.25 AMA/ANCC/AANP FREE credits
for participating in this free virtual CME/CE activity!

Tuesday, October 27, 2020 4:00-5:15pm EST


Thursday, October 29, 2020 4:00-5:15pm EST

Register Now

SCIENTIFIC SESSION
UC Disease Overview & Classifications
Treatment Options for Advanced or Metastatic UC
First-Line Treatments
Maintenance and Second-Line Options
Emerging Treatments
Managing, Monitoring, & Mitigating Adverse Events
Question & Answer Session/Closing Remarks

Program Overview
When urothelial carcinoma (UC) is diagnosed in advanced or metastatic stages, a heavily cytotoxic "sledgehammer" approach has traditionally been used. New and emerging agents include more selective, targeted treatments that take advantage of recently unraveled translational insights into UC. The introduction of these agents and others still in development complicate an already complex condition. This activity will help advanced practice providers (APPs) who treat patients with UC to select and sequence these treatments as well as how to identify and manage potential treatment-related adverse events.

Faculty

Dr. Pllimack Headshot

Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Professor, Department of Hematology/Oncology
Director, Genitourinary Clinical Research
Fox Chase Cancer Center
Temple University Health System
Philadelphia, Pennsylvania

 

Nurse Roethke Headshot

Susan K. Roethke, CRNP, MSN, ANP-BC, AOCNP
Certified Registered Nurse Practitioner
Genitourinary Medical Oncology
Dept of Hematology/Oncology
Fox Chase Cancer Center
Temple University Health System
Philadelphia, Pennsylvania

Target Audience

Advanced practice providers caring for patients with urothelial carcinoma.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors (ICIs) used in the treatment of urothelial cancer (UC)
  • Outline efficacy and safety findings from key clinical trials of approved and investigational ICIs, antibody-drug conjugates (ADCs), and fibroblast growth factor receptor (FGFR) inhibitors developed for the treatment of advanced or metastatic UC
  • Implement a patient-focused strategy for identifying, monitoring, and mitigating adverse events that can be caused by novel UC treatments
Register Now
Accreditation
Physician Continuing Education
Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

AANP Logo
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hour(s) (which includes* hour(s) of pharmacology).
*Pharmacology hours are TBD after clinical content review.

Instructions to Receive Credit
In order to receive credit for this activity, the participant must complete the pretest, attend the virtual live symposium, and successfully complete the posttest and evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Disclosure of Conflict of Interest

Integrity Continuing Education and Global Education Group requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

A detailed disclosure for all persons in control of content, including faculty presenters, will be provided at the live virtual event.

Contact Information

For information about ACCME accreditation of this activity,
please contact Integrity Continuing Education at (855) 835-4004
or information@integrityce.com.

For information about the accreditation (ANCC and AANP) of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

This CME activity is provided by Integrity Continuing Education.

This CE activity is jointly provided by Global Education Group and Integrity Continuing Education.

Supporter Acknowledgement
This activity is supported by independent educational grants from Astellas,
Merck Sharp & Dohme, and Seattle Genetics.

Integrity Continuing Education
106 Apple Street, Suite 300, Tinton Falls, NJ 07724